Drug repurposing for rheumatoid arthritis: Identification of new drug candidates via bioinformatics and text mining analysis

References

• Banchereau R, Cepika A-M, Banchereau J, et al. Understanding human autoimmunity and autoinflammation through transcriptomics. Annu Rev Immunol. 2017;35:337–370.
   PubMed Web of Science ®Google Scholar
• Liu Y, Yin H, Zhao M, et al. TLR2 and TLR4 in autoimmune diseases: a comprehensive review. Clin Rev Allergy Immunol. 2014;47(2):136–147.
   PubMed Web of Science ®Google Scholar
• Krishna V, Yin X, Song Q, et al. Integration of the transcriptome and genome-wide landscape of BRD2 and BRD4 binding motifs identifies key superenhancer genes and reveals the mechanism of bet inhibitor action in rheumatoid arthritis synovial fibroblasts. J Immunol. 2021;206(2):422–431.
   PubMed Web of Science ®Google Scholar
• Cohn M. Autoimmunity: Rationalizing possible pathways from initiation to disease. J Theor Biol. 2015;375:40–51.
   PubMed Web of Science ®Google Scholar
• Udalova IA, Mantovani A, Feldmann M. Macrophage heterogeneity in the context of rheumatoid arthritis. Nat Rev Rheumatol. 2016;12(8):472–485.
   PubMed Web of Science ®Google Scholar
• Song X, Lin Q. Genomics, transcriptomics and proteomics to elucidate the pathogenesis of rheumatoid arthritis. Rheumatol Int. 2017;37(8):1257–1265.
   PubMed Web of Science ®Google Scholar
• Frank-Bertoncelj M, Klein K, Gay S. Interplay between genetic and epigenetic mechanisms in rheumatoid arthritis. Epigenomics. 2017;9(4):493–504.
   PubMed Web of Science ®Google Scholar
• Craddock N, Hurles ME, Cardin N, et al. Genome-wide association study of CNVs in 16,000 cases of eight common diseases and 3,000 shared controls. Nature. 2010;464(7289):713–720.
   PubMed Web of Science ®Google Scholar
• Eyre S, Bowes J, Diogo D, Wellcome Trust Case Control Consortium, et al. High-density genetic mapping identifies new susceptibility loci for rheumatoid arthritis. Nat Genet. 2012;44(12):1336–1340.,
   PubMed Web of Science ®Google Scholar
• Ai R, Hammaker D, Boyle DL, et al. Joint-specific DNA methylation and transcriptome signatures in rheumatoid arthritis identify distinct pathogenic processes. Nat Commun. 2016;7:11849
   PubMed Web of Science ®Google Scholar
• Teixeira VH, Olaso R, Martin-Magniette M-L, et al. Transcriptome analysis describing new immunity and defense genes in peripheral blood mononuclear cells of rheumatoid arthritis patients. PloS One. 2009;4(8):e6803. Aug
   PubMed Web of Science ®Google Scholar
• Pauley KM, Cha S, Chan EKL. MicroRNA in autoimmunity and autoimmune diseases. J Autoimmun. 2009;32(3-4):189–194.
   PubMed Web of Science ®Google Scholar
• Chen J-Q, Papp G, Szodoray P, et al. The role of microRNAs in the pathogenesis of autoimmune diseases. Autoimmun Rev. 2016;15(12):1171–1180.
   PubMed Web of Science ®Google Scholar
• Paul SM, Mytelka DS, Dunwiddie CT, et al. How to improve R&D productivity: the pharmaceutical industry's grand challenge. Nat Rev Drug Discov. 2010;9(3):203–214.
   PubMed Web of Science ®Google Scholar
• Nosengo N. Can you teach old drugs new tricks? Nature. England. 2016;534(7607):314–316.
   PubMed Web of Science ®Google Scholar
• Gupta SC, Sung B, Prasad S, et al. Cancer drug discovery by repurposing: teaching new tricks to old dogs. Trends Pharmacol Sci. 2013;34(9):508–517.
   PubMed Web of Science ®Google Scholar
• Demirel A, Kirnap M. Traditional and up-to-date treatment in rheumatoid arthtiris. Saglık bilimleri dergisi. (Journal of Health Sciences). 2010;19(1):74–84.
   Google Scholar
• Comertpay B, Gov E. Identification of key biomolecules in rheumatoid arthritis through the reconstruction of comprehensive disease-specific biological networks. Autoimmunity. 2020; 53(3):156–166.
   PubMed Web of Science ®Google Scholar
• Auwul MR, Rahman MR, Gov E, et al. Bioinformatics and machine learning approach identifies potential drug targets and pathways in COVID-19. Brief Bioinform. 2021;22(5)
   PubMed Web of Science ®Google Scholar
• Erceylan ÖF, Savaş A, Göv E. Targeting the tumor stroma: integrative analysis reveal GATA2 and TORYAIP1 as novel prognostic targets in breast and ovarian cancer. Turk J Biol. 2021;45(2):127–137.
   PubMed Web of Science ®Google Scholar
• Comertpay B, Gulfidan G, Arga KY, et al. Cancer stem cell transcriptome profiling reveals seed genes of tumorigenesis: New avenues for cancer precision medicine. OMICS. 2021;25(6):372–388.
   PubMed Web of Science ®Google Scholar
• Gulfidan G, Beklen H, Sinha I, et al. Differential protein interactome in esophageal squamous cell carcinoma offers novel systems biomarker candidates with high diagnostic and prognostic performance. OMICS. 2021;25(8):495–512.
   PubMed Web of Science ®Google Scholar
• Barrett T, Wilhite SE, Ledoux P, et al. NCBI GEO: archive for functional genomics data sets-update. Nucleic Acids Res. 2013;41(Database issue):D991–5.
   PubMed Web of Science ®Google Scholar
• Woetzel D, Huber R, Kupfer P, et al. Identification of rheumatoid arthritis and osteoarthritis patients by transcriptome-based rule set generation. Arthritis Res Ther. 2014;16(2):R84
   PubMed Web of Science ®Google Scholar
• Broeren MGA, de Vries M, Bennink MB, Arntz OJ, et al. Disease-Regulated gene therapy with anti-Inflammatory interleukin-10 under the control of the CXCL10 promoter for the treatment of rheumatoid Arthritis. Hum Gene Ther. 2016;27(3):244–254.
   PubMed Web of Science ®Google Scholar
• Ungethuem U, Haeupl T, Witt H, et al. Molecular signatures and new candidates to target the pathogenesis of rheumatoid arthritis. Physiol Genomics. 2010;42A(4):267–282.
   PubMed Web of Science ®Google Scholar
• Yarilina A, Park-Min K-H, Antoniv T, et al. TNF activates an IRF1-dependent autocrine loop leading to sustained expression of chemokines and STAT1-dependent type I interferon-response genes. Nat Immunol. 2008;9(4):378–387.
   PubMed Web of Science ®Google Scholar
• Kang K, Park SH, Chen J, et al. Interferon-γ represses M2 gene expression in human macrophages by disassembling enhancers bound by the transcription factor MAF. Immunity. 2017;47(2):235–250.e4.
   PubMed Web of Science ®Google Scholar
• Tasaki S, Suzuki K, Kassai Y, et al. Multi-omics monitoring of drug response in rheumatoid arthritis in pursuit of molecular remission. Nat Commun. 2018;9(1):2755
   PubMedGoogle Scholar
• Bolstad BM, Irizarry RA, Åstrand M, et al. A comparison of normalization methods for high density oligonucleotide array data based on variance and bias. Bioinformatics. 2003;19(2):185–193.
   PubMed Web of Science ®Google Scholar
• Smyth GK. Linear models and empirical Bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol. 2004;3(1):1–25.
   Google Scholar
• Kamburov A, Pentchev K, Galicka H, et al. ConsensusPathDB: toward a more complete picture of cell biology. Nucleic Acids Res. 2011;39(Database issue):D712–7.
   PubMedGoogle Scholar
• Oughtred R, Rust J, Chang C, et al. The BioGRID database: a comprehensive biomedical resource of curated protein, genetic, and chemical interactions. Protein Sci. 2021;30(1):187–200.
   PubMed Web of Science ®Google Scholar
• Smoot ME, Ono K, Ruscheinski J, et al. Cytoscape 2.8: new features for data integration and network visualization. Bioinformatics. 2011;27(3):431–432.
   PubMed Web of Science ®Google Scholar
• Bovolenta LA, Acencio ML, Lemke N. HTRIdb: an open-access database for experimentally verified human transcriptional regulation interactions. BMC Genomics. 2012;13:405.
   PubMed Web of Science ®Google Scholar
• Gov E, Arga KY. Interactive cooperation and hierarchical operation of microRNA and transcription factor crosstalk in human transcriptional regulatory network. IET Syst Biol. 2016;10(6):219–228.
   PubMed Web of Science ®Google Scholar
• Chou C-H, Chang N-W, Shrestha S, et al. miRTarBase 2016: updates to the experimentally validated miRNA-target interactions database. Nucleic Acids Res. 2016;44(D1):D239–47.
   PubMed Web of Science ®Google Scholar
• Cotto KC, Wagner AH, Feng Y-Y, et al. DGIdb 3.0: a redesign and expansion of the drug-gene interaction database. Nucleic Acids Res. 2018;46(D1):D1068–73.
   PubMedGoogle Scholar
• urllib3 1.26.7 [Internet]. Available from: https://pypi.org/project/urllib3/.
   Google Scholar
• Canese K, Weis S PubMed : the bibliographic database. In: The NCBI handbook. 2013. p. 1–12.
   Google Scholar
• Cock PJA, Antao T, Chang JT, et al. Biopython: freely available python tools for computational molecular biology and bioinformatics. Bioinformatics. 2009;25(11):1422–1423. Jun
   PubMed Web of Science ®Google Scholar
• Bardou P, Mariette J, Escudié F, et al. SOFTWARE open access jvenn: an interactive venn diagram viewer. BMC Bioinformatics. [Internet]. 2014;15(293):293–297. Available from: http://www.biomedcentral.com/1471-2105/15/293
   PubMedGoogle Scholar
• Zhao Z, Ukidve A, Kim J, et al. Targeting strategies for Tissue-Specific drug delivery. Cell. 2020;181(1):151–167.
   PubMed Web of Science ®Google Scholar
• Corticosteroids [Internet]. LiverTox: Clinical and research information on Drug-Induced liver injury. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012. [cited 2021 Oct 11]. Available from: https://pubmed.ncbi.nlm.nih.gov/31643719/
   Google Scholar
• Harris EDJ, Emkey RD, Nichols JE, et al. Low dose prednisone therapy in rheumatoid arthritis: a double blind study. J Rheumatol. 1983;10(5):713–721. Oct
   PubMed Web of Science ®Google Scholar
• van Everdingen AA, Jacobs JWG, Siewertsz Van Reesema DR, et al. Low-dose prednisone therapy for patients with early active rheumatoid arthritis: clinical efficacy, disease-modifying properties, and side effects: a randomized, double-blind, placebo-controlled clinical trial. Ann Intern Med. 2002;136(1):1–12.
   PubMed Web of Science ®Google Scholar
• Pincus T, Marcum SB, Callahan LF. Longterm drug therapy for rheumatoid arthritis in seven rheumatology private practices: II. Second line drugs and prednisone. J Rheumatol. 1992;19(12):1885–1894.
   PubMed Web of Science ®Google Scholar
• Cheah CY, Seymour JF, Wang ML. Mantle cell lymphoma. J Clin Oncol. 2016;34(11):1256–1269.
   PubMed Web of Science ®Google Scholar
• CALQUENCE® (acalabrutinib) capsules, for oral use Initial U.S. Approval: 2017. [Internet]. AstraZeneca Pharmaceuticals LP; 4523127 [cited 2021 Oct 10]. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210259s006s007lbl.pdf.
   Google Scholar
• ACP-196 Versus Placebo in Subjects With Rheumatoid Arthritis on Background MethotrexateNo Title [Internet]. U.S. National Library of Medicine ClinicalTrials.gov. [cited 2021. Oct 10]. Available at: https://clinicaltrials.gov/ct2/show/study/NCT02387762.
   Google Scholar
• Forsythe P, Paterson S. Ciclosporin 10 years on: indications and efficacy. The Veterinary Record. 2014;174(S2):13–21. Mar
   PubMedGoogle Scholar
• Johns KR, Littlejohn GO. The safety and efficacy of cyclosporine (neoral) in rheumatoid arthritis. The. J Rheumatol. 1999;26(10):2110–2113.
   PubMed Web of Science ®Google Scholar
• Lichtiger S, Present DH, Kornbluth A, et al. Cyclosporine in severe ulcerative colitis refractory to steroid therapy. The. N Engl J Med. 1994;330(26):1841–1845.
   PubMed Web of Science ®Google Scholar
• Kappers-Klunne MC, van’t Veer MB. Cyclosporin a for the treatment of patients with chronic idiopathic thrombocytopenic purpura refractory to corticosteroids or splenectomy. Br J Haematol. 2001;114(1):121–125.
   PubMed Web of Science ®Google Scholar
• Lee SH, Chung H, Yu HG. Clinical outcomes of cyclosporine treatment for noninfectious uveitis. Korean J Ophthalmol. 2012;26(1):21–25.
   PubMedGoogle Scholar
• Yang TH, Wu TH, Chang YL, et al. Cyclosporine for the treatment of lupus nephritis in patients with systemic lupus erythematosus. CN. 2018;89(4):277–285.
   Google Scholar
• Tyner JW, Bumm TG, Deininger J, Wood L, et al. CYT387, a novel JAK2 inhibitor, induces hematologic responses and normalizes inflammatory cytokines in murine myeloproliferative neoplasms. Blood. 2010;115(25):5232–5240. Jun
   PubMed Web of Science ®Google Scholar
• Gupta V, Mesa RA, Deininger MWN, et al. A phase 1/2, open-label study evaluating twice-daily administration of momelotinib in myelofibrosis. Haematologica. 2017;102(1):94–102. Jan
   PubMed Web of Science ®Google Scholar
• Tymoszuk P, Petzer V, Asshoff M, et al. Momelotinib, a janus kinase 1/2 and activin receptor 1 inhibitor, ameliorates joint inflammation, systemic Th17 differentiation and Arthritis-Linked anemia in Pre-Clinical autoimmune RA. Ann Rheum Dis. 2020;79(Suppl 1):940.1–940. [Internet]. – Available from: http://ard.bmj.com/content/79/Suppl_1/940.1.abstract
   Google Scholar
• Berglöf A, Hamasy A, Meinke S, et al. Targets for ibrutinib beyond B cell malignancies. Scand J Immunol. 2015;82(3):208–217. Sep
   PubMed Web of Science ®Google Scholar
• Papanota A-M, Ntanasis-Stathopoulos I, Kastritis E, et al. Evaluating ibrutinib in the treatment of symptomatic Waldenstrom's macroglobulinemia. J Blood Med. 2019;10:291–300.
   PubMed Web of Science ®Google Scholar
• Miklos D, Cutler CS, Arora M, et al. Ibrutinib for chronic graft-versus-host disease after failure of prior therapy. Blood. 2017;130(21):2243–2250. Nov
   PubMed Web of Science ®Google Scholar
• Kim S, Chen J, Cheng T, et al. PubChem in 2021: new data content and improved web interfaces. Nucleic Acids Res. 2021;49(D1):D1388–D1395.
   PubMed Web of Science ®Google Scholar
• Kim DS, Kwon J-E, Lee SH, et al. Attenuation of rheumatoid inflammation by sodium butyrate through reciprocal targeting of HDAC2 in osteoclasts and HDAC8 in T cells. Front Immunol. 2018;9:1525.
   PubMed Web of Science ®Google Scholar
• Wishart DS, Feunang YD, Guo AC, et al. DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res. 2018;46(D1):D1074–82.
   PubMed Web of Science ®Google Scholar
• Sharma S, Mulik S, Kumar N, et al. An anti-inflammatory role of VEGFR2/src kinase inhibitor in herpes simplex virus 1-induced immunopathology. J Virol. 2011;85(12):5995–6007. Jun
   PubMed Web of Science ®Google Scholar
• Mousa SA, Mousa SS. Current status of vascular endothelial growth factor inhibition in age-related macular degeneration. BioDrugs : Clin Immunotherapeut BiopharmaceuticalsGene Therapy. 2010;24(3):183–194.
   PubMed Web of Science ®Google Scholar
• Gijsen M, King P, Perera T, et al. HER2 phosphorylation is maintained by a PKB negative feedback loop in response to anti-HER2 herceptin in breast cancer. PLoS Biol. 2010;8(12):e1000563
   PubMed Web of Science ®Google Scholar
• Gadina M, Schwartz DM, O'Shea JJ. Decernotinib: a Next-Generation Jakinib. Arthritis Rheumatol. 2016;68(1):31–34.
   PubMed Web of Science ®Google Scholar
• Genovese MC, van Vollenhoven RF, Pacheco-Tena C, et al. VX-509 (decernotinib), an oral selective JAK-3 inhibitor, in combination with methotrexate in patients with rheumatoid arthritis. Arthritis & Rheumatology (Hoboken, NJ. 2016;68(1):46–55.
   PubMed Web of Science ®Google Scholar
• Fleischmann RM, Damjanov NS, Kivitz AJ, et al. A randomized, double-blind, placebo-controlled, twelve-week, dose-ranging study of decernotinib, an oral selective JAK-3 inhibitor, as monotherapy in patients with active rheumatoid arthritis. Arthr Rheumatol. 2015;67(2):334–343. ). Feb
   PubMed Web of Science ®Google Scholar
• Genovese MC, Yang F, Østergaard M, et al. Efficacy of VX-509 (decernotinib) in combination with a disease-modifying antirheumatic drug in patients with rheumatoid arthritis: clinical and MRI findings. Ann Rheum Dis. 2016;75(11):1979–1983. Nov
   PubMed Web of Science ®Google Scholar
• Mogul A, Corsi K, McAuliffe L. Baricitinib: the second FDA-Approved JAK inhibitor for the treatment of rheumatoid arthritis. Ann Pharmacother. 2019;53(9):947–953. Sep
   PubMed Web of Science ®Google Scholar
• Fleischmann R, Schiff M, van der Heijde D, et al. Baricitinib, methotrexate, or combination in patients with rheumatoid arthritis and no or limited prior disease-modifying antirheumatic drug treatment. Arthritis Rheumatol. 2017;69(3):506–517. Mar
   PubMed Web of Science ®Google Scholar
• Schiff M, Takeuchi T, Fleischmann R, et al. Patient-reported outcomes of baricitinib in patients with rheumatoid arthritis and no or limited prior disease-modifying antirheumatic drug treatment. Arthritis Res Ther. 2017;19(1):208
   PubMedGoogle Scholar
• Keystone EC, Taylor PC, Drescher E, et al. Safety and efficacy of baricitinib at 24 weeks in patients with rheumatoid arthritis who have had an inadequate response to methotrexate. Ann Rheum Dis. 2015;74(2):333–340.
   PubMed Web of Science ®Google Scholar
• Itacitinib [Internet]. Bethesda (MD): National Library of Medicine (US), National Center for Biotechnology Information; 2004. PubChem Compound Summary for CID 53380437. [cited 2021 Oct 10]. Available at: https://pubchem.ncbi.nlm.nih.gov/compound/Itacitinib.
   Google Scholar
• A Study Exploring the Safety, Tolerability, and Efficacy of a 28 Day Course Followed by an Additional 56 Day Course of Itacitinib in Subjects With Active Rheumatoid Arthritis [Internet]. U.S. National Library of Medicine ClinicalTrials.gov. 2012. [cited 2021 Oct 10]. Available at: https://clinicaltrials.gov/ct2/show/NCT01626573.
   Google Scholar
• McMullin MF, Harrison CN, Niederwieser D, et al. The use of erythropoiesis-stimulating agents with ruxolitinib in patients with myelofibrosis in COMFORT-II: an open-label, phase 3 study assessing efficacy and safety of ruxolitinib versus best available therapy in the treatment of myelofibrosis. Exp Hematol Oncol. 2015;4:26.
   PubMed Web of Science ®Google Scholar
• Weinacht KG, Charbonnier L-M, Alroqi F, et al. Ruxolitinib reverses dysregulated T helper cell responses and controls autoimmunity caused by a novel signal transducer and activator of transcription 1 (STAT1) gain-of-function mutation. J Allergy Clin Immunol. 2017; May139(5):1629–1640.e2.
   PubMed Web of Science ®Google Scholar
• Higgins E, Al Shehri T, McAleer MA, et al. Use of ruxolitinib to successfully treat chronic mucocutaneous candidiasis caused by gain-of-function signal transducer and activator of transcription 1 (STAT1) mutation. J Allergy Clin Immunol. 2015;135(2):551–553. Vol.
   PubMed Web of Science ®Google Scholar
• A Study Exploring the Safety, Tolerability and Efficacy of a 4 Week Course of INCB018424 in Subjects With Active Rheumatoid Arthritis [Internet]. U.S. National Library of Medicine ClinicalTrials.gov. 2015. [cited 2021 Oct 10]. Available at: https://clinicaltrials.gov/ct2/show/NCT00550043.
   Google Scholar
• Cheon JH, Kim JY, Lee B-M, et al. P-gp inhibition by XL019, a JAK2 inhibitor, increases apoptosis of vincristine-treated resistant KBV20C cells with increased p21 and pH2AX Expression. Anticancer Res. 2017;37(12):6761–6769.
   PubMed Web of Science ®Google Scholar
• Tseng S, Pak G, Washenik K, et al. Rediscovering thalidomide: a review of its mechanism of action, side effects, and potential uses. J Am Acad Dermatol. 1996;35(6):969–979.
   PubMed Web of Science ®Google Scholar
• Richardson P, Hideshima T, Anderson K. Thalidomide: emerging role in cancer medicine. Annu Rev Med. 2002;53:629–657.
   PubMed Web of Science ®Google Scholar
• Gutiérrez-Rodríguez O. Thalidomide. A promising new treatment for rheumatoid arthritis. Arthritis Rheum. 1984;27(10):1118–1121.
   PubMedGoogle Scholar
• Gutiérrez-Rodríguez O, Starusta-Bacal P, Gutiérrez-Montes O. Treatment of refractory rheumatoid arthritis–the thalidomide experience. J Rheumatol. 1989; 16(2):158–163.
   PubMed Web of Science ®Google Scholar
• Lehman TJA, Schechter SJ, Sundel RP, et al. Thalidomide for severe systemic onset juvenile rheumatoid arthritis: a multicenter study. The Journal of Pediatrics. 2004;145(6):856–857.
   PubMed Web of Science ®Google Scholar
• Klepser TB, Kelly MW. Metformin hydrochloride: an antihyperglycemic agent. Am J Health Syst Pharm. 1997;54(8):893–903.
   PubMed Web of Science ®Google Scholar
• Negrotto L, Farez MF, Correale J. Immunologic effects of metformin and pioglitazone treatment on metabolic syndrome and multiple sclerosis. JAMA Neurol. 2016; 73(5):520–528.
   PubMed Web of Science ®Google Scholar
• Kang KY, Kim Y-K, Yi H, Kim J, et al. Metformin downregulates Th17 cells differentiation and attenuates murine autoimmune arthritis. Int Immunopharmacol. 2013; 16(1):85–92.
   PubMed Web of Science ®Google Scholar
• Zhang L, Zhang J, Ye Z, et al. Pharmacology of ME-344, a novel cytotoxic isoflavone. Adv Cancer Res. 2019;142:187–207.
   PubMed Web of Science ®Google Scholar
• Alvero AB, Montagna MK, Chen R, et al. NV-128, a novel isoflavone derivative, induces caspase-independent cell death through the akt/mammalian target of rapamycin pathway. Cancer. 2009;115(14):3204–3216. Jul
   PubMed Web of Science ®Google Scholar